T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$3.76B |
| 2 |
Cigna
CI
|
+$1.44B |
| 3 |
Bristol-Myers Squibb
BMY
|
+$1.26B |
| 4 |
Occidental Petroleum
OXY
|
+$763M |
| 5 |
Danaher
DHR
|
+$762M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
PCYC
PHARMACYCLICS INC
PCYC
|
+$2.46B |
| 2 |
Wynn Resorts
WYNN
|
+$1.11B |
| 3 |
Netflix
NFLX
|
+$1.03B |
| 4 |
PCP
PRECISION CASTPARTS CORP
PCP
|
+$975M |
| 5 |
TWTR
Twitter, Inc.
TWTR
|
+$909M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 22.87% |
| 2 | Financials | 13.64% |
| 3 | Consumer Discretionary | 13.54% |
| 4 | Industrials | 10.67% |
| 5 | Technology | 10.39% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
SVU
1776
DELISTED
SUPERVALU Inc.
SVU
| $891K | ﹤0.01% |
15,728
+3,700
| +31% | +$247K |
|
|
CSR
1777
Centerspace
CSR
$941M
| $887K | ﹤0.01% |
12,425
+239
| +2% | +$17.3K |
|
1778
Dolby
DLB
$5.72B
| $887K | ﹤0.01% |
22,362
+3,000
| +15% | +$119K |
|
1779
Emcor
EME
$37B
| $887K | ﹤0.01% |
18,560
| – | – |
|
1780
TC Energy
TRP
$65.7B
| $886K | ﹤0.01% |
21,800
-2,000
| -8% | -$88K |
|
1781
CDW
CDW
$17.2B
| $884K | ﹤0.01% |
25,800
| – | – |
|
1782
Idacorp
IDA
$8.15B
| $882K | ﹤0.01% |
15,710
| – | – |
|
|
MZTI
1783
The Marzetti Company
MZTI
$3.24B
| $881K | ﹤0.01% |
9,700
-300
| -3% | -$27.5K |
|
1784
Cirrus Logic
CRUS
$6.09B
| $879K | ﹤0.01% |
25,840
+2,200
| +9% | +$77.5K |
|
1785
Halozyme
HALO
$11.3B
| $878K | ﹤0.01% |
38,900
+10,200
| +36% | +$179K |
|
1786
Trustmark
TRMK
$2.81B
| $878K | ﹤0.01% |
35,149
+7,400
| +27% | +$181K |
|
1787
Cinemark Holdings
CNK
$4.35B
| $872K | ﹤0.01% |
21,700
| – | – |
|
1788
Deluxe
DLX
$1.09B
| $870K | ﹤0.01% |
14,028
| – | – |
|
1789
Integra LifeSciences
IART
$1.44B
| $869K | ﹤0.01% |
31,559
+8,318
| +36% | +$222K |
|
1790
Bank OZK
OZK
$5.73B
| $869K | ﹤0.01% |
19,000
| – | – |
|
1791
MasTec
MTZ
$23.2B
| $862K | ﹤0.01% |
43,400
+8,400
| +24% | +$157K |
|
|
VR
1792
DELISTED
Validus Hold Ltd
VR
| $858K | ﹤0.01% |
19,500
| – | – |
|
|
LSI
1793
DELISTED
Life Storage, Inc.
LSI
| $852K | ﹤0.01% |
14,700
| – | – |
|
|
AXLL
1794
DELISTED
AXIALL CORP COM STK (DE)
AXLL
| $844K | ﹤0.01% |
23,400
| – | – |
|
1795
Popular Inc
BPOP
$11.4B
| $842K | ﹤0.01% |
29,185
| – | – |
|
1796
Regal Rexnord
RRX
$11.4B
| $842K | ﹤0.01% |
11,600
| – | – |
|
|
EFII
1797
DELISTED
Electronics for Imaging
EFII
| $840K | ﹤0.01% |
19,300
| – | – |
|
1798
Myriad Genetics
MYGN
$301M
| $836K | ﹤0.01% |
24,590
-103,010
| -81% | -$3.5M |
|
|
IPXL
1799
DELISTED
Impax Laboratories, Inc.
IPXL
| $822K | ﹤0.01% |
17,900
+1,900
| +12% | +$90.2K |
|
1800
iShares Russell 2000 ETF
IWM
$82.4B
| $817K | ﹤0.01% |
6,541
+302
| +5% | +$37.7K |
|
Similar funds
T. Rowe Price Associates's Q2 2015 Portfolio in Review
As of Q2 2015, T. Rowe Price Associates held 2,615 positions worth $486B, up 0.44% from $484B the previous quarter. Its ten largest holdings account for 14% of the portfolio.
T. Rowe Price Associates's Q2 2015 filing shows 76 new, 1,051 increased, 777 reduced and 79 closed positions. Its largest new stake was Allergan plc: 548,825 shares worth $570M. The largest sale was PHARMACYCLICS INC, an estimated $2.46B.
By sector, the portfolio is most concentrated in Healthcare at 23% of assets, up from 21% a quarter earlier, followed by Financials and Consumer Discretionary.
- T. Rowe Price Associates's largest Q2 2015 buy was Allergan plc: 548,825 shares worth $570M.
- T. Rowe Price Associates added most to Microsoft in Q2 2015, an estimated $3.76B increase.
- T. Rowe Price Associates's biggest Q2 2015 reduction was Wynn Resorts, cutting an estimated $1.11B.
- T. Rowe Price Associates fully exited PHARMACYCLICS INC in Q2 2015, selling an estimated $2.46B.
- T. Rowe Price Associates's ten largest holdings make up 14% of its $486B portfolio in Q2 2015.
- T. Rowe Price Associates opened 76 new positions and closed 79 in Q2 2015.
- T. Rowe Price Associates's portfolio value rose 0.44% quarter-over-quarter to $486B.
Based on T. Rowe Price Associates's 13F filing for Q2 2015, filed 14 Aug 2015.